GE HealthCare Technologies Inc. - Common Stock (GEHC)

GE HealthCare (Nasdaq: GEHC) today announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company’s Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent (UEA). This approval will help improve the clarity and diagnostic accuracy of echocardiograms in pediatric patients, giving cardiologists a fuller picture of ventricular function when assessing possible heart abnormalities or disease.

GE HealthCare (Nasdaq: GEHC) and Raydiant Oximetry, Inc. today announced a joint development initiative to enhance fetal monitoring capabilities that could strengthen the support of clinical decision-making during labor. This effort leverages the combined expertise and technology of the two companies to advance fetal oxygen saturation monitoring technology with the goal of enhancing the detection of fetal distress during childbirth.

GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA™ Sprint, an FDA 510(k) pending1 ultra-premium wide bore 1.5T high-performance gradient MRI system, at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025. This innovative technology is designed to unlock advanced imaging possibilities in cardiology, oncology and other clinical and research areas.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:POAI),(NYSE:TDOC),(NASDAQ:GEHC) EQNX::TICKER_END

GE HealthCare (Nasdaq: GEHC) today announced an intended expansion of its radiation oncology portfolio as well as the introduction of the new AI-enabled MR Contour DL™ at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2025 Congress in Vienna, Austria. The company will also showcase its updated Intelligent Radiation Therapy (iRT), a software solution that standardizes complex workflows, helping to enable a shorter timeline from diagnosis to treatment and more precise radiation therapy.

PALM BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial Intelligence (AI) is becoming more essential in the medical markets every day, it seems. AI algorithms have demonstrated the capability to analyze vast amounts of medical data, including patient records and genetic information. This efficiency allows healthcare professionals to diagnose conditions more quickly and accurately, leading to better patient outcomes. AI-powered diagnostic tools can detect subtle patterns and indicators of diseases; this offers early detection and further works on early prevention of diseases. AI systems also help in assisting healthcare professionals with valuable tools, all these factors that offer improved diagnosis process act as a driver for the market’s growth. A report from MarketsAndMarkets projected that the global AI in medical diagnostics market is forecasted to grow at a robust CAGR of 22.5%, reaching US$1.71 billion in 2024 and an impressive US$4.72 billion by 2029. The report said: “Government initiatives towards increasing Al-based technologies, access to finance for Al-based startups, big data influx, and growing cross-industry alliances and collaborations are key drivers of this market's growth. Growth in the AI in medical diagnostics market is primarily driven by the growing demand for AI tools, increasing focus on reducing the workload of radiologists, influx of large & complex datasets, funding for AI based startups, and growing cross-industry partnerships & collaborations.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), Predictive Oncology Inc. (NASDAQ: POAI), Teladoc Health, Inc. (NYSE: TDOC), GE HealthCare (NASDAQ: GEHC).

GE HealthCare (Nasdaq: GEHC) today reported financial results for the first quarter ended March 31, 2025.

GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences.

GE HealthCare (Nasdaq: GEHC), a global leader in breast health technology, will feature its latest advancements in diagnostic accuracy and patient-centered breast care during the 2025 Society of Breast Imaging Symposium in Colorado Springs, Co., April 24-27, 2025. This year’s showcase will feature new innovations designed to improve breast cancer detection, streamline workflows, and enhance overall patient care.

GE HealthCare (Nasdaq: GEHC) will announce its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

Cincinnati Children’s and GE HealthCare (Nasdaq: GEHC) will form a strategic research program focused on driving clinical and technical research to advance innovation for pediatric care delivery across modalities, including magnetic resonance imaging (MRI), ultrasound, molecular imaging (MI), and computed tomography (CT). The research program will establish the first pediatric Care Innovation Hub nationwide, representing a new model established by GE HealthCare and Cincinnati Children’s to combine their talents and resources to accelerate the impact of innovation and scientific activities for the benefit of pediatric patients.

GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025.

GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.

At the American College of Cardiology 2025 meeting, GE HealthCare (Nasdaq: GEHC) will proudly introduce Revolution™ Vibe,i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries. Combined with the company’s impressive ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Workflow's AI-powered solutions, Revolution Vibe enables fast, accurate diagnoses, a more comfortable patient experience, and more efficient workflows.v

The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2025 payable on May 15, 2025 to all shareholders of record as of April 25, 2025.

GE HealthCare (Nasdaq: GEHC) today announced the U.S. launch of Flyrcado™ (flurpiridaz F 18) injection at the 2025 American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place March 29-31 in Chicago. Additionally, the company will showcase new AI-powered innovations, reflecting its strategy to leverage AI to help increase efficiency and enable seamless integration of data across the cardiology care pathway. GE HealthCare has been investing in AI for years and has topped the FDA list of AI-enabled device authorizations for three years in a row with 85 authorizations.i

GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts.

GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound.

GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards.

GE HealthCare (Nasdaq: GEHC) today announced its new Genesis solutions, a portfolio of cloud enterprise imaging software-as-a-service (SaaS) solutions. Four features will be offered when commercially released – edge, storage, vendor neutral archive and data migration.i These cloud solutions, are designed to help enhance healthcare organizations’ efficiency and precision, streamline workflows, and optimize the use of capital and IT resources.

GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song, a Johnson & Johnson veteran for over 20 years, has been named GE HealthCare’s new president and CEO, China, and will join the company on April 1, 2025, ahead of leading the region starting July 1 following Yihao’s departure.

GE HealthCare (Nasdaq: GEHC) today unveiled Freelium™,ii a next-generation sealed magnet platform, that aims to enable high-quality Magnetic Resonance (MR) imaging with less than 1% of helium used in conventional magnet technology to help support diagnostic accuracy and sustainability goals. Debuting at the European Congress of Radiology (ECR), Freelium marks the evolution of GE HealthCare’s established lightweight intelligent platform magnet technology, which was first introduced in 2020, now with over 2,000 installations worldwide at 1.5T and 3.0T magnetic fields.

GE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for the detection of coronary artery disease (CAD), at early adopter imaging centers in the US. This milestone follows the recent FDA approval of Flyrcado, which is indicated for patients with known or suspected CAD, and delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI, the predominant procedure used in nuclear cardiology today.

GE HealthCare (Nasdaq: GEHC) today reported financial results for the fourth quarter and full year ended December 31, 2024.

GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at Citi’s 2025 Medtech and Life Sciences Access Day on February 27, 2025 at 2:15pm CT / 3:15 pm ET.